254 related articles for article (PubMed ID: 6770131)
21. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
[TBL] [Abstract][Full Text] [Related]
22. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.
Jones RJ; Roe EA
Br J Exp Pathol; 1975 Feb; 56(1):34-43. PubMed ID: 812544
[TBL] [Abstract][Full Text] [Related]
23. IgE antibody production to exoenzymes and common antigen (OEP) of Pseudomonas aeruginosa in mice.
Cho YJ; Oh YH; Abe C; Homma JY; Usui M; Matuhasi T
Jpn J Exp Med; 1978 Dec; 48(6):491-6. PubMed ID: 108438
[TBL] [Abstract][Full Text] [Related]
24. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
[TBL] [Abstract][Full Text] [Related]
25. [Use of a vaccine for prevention of Pseudomonas aeruginosa infection of burn wounds in mice].
Grochowski J; Bilinska M; Stankiewicz D; Arkusiewicz E
Pol Przegl Chir; 1979 Jun; 51(6):623-7. PubMed ID: 116210
[No Abstract] [Full Text] [Related]
26. Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge.
Neely AN; Holder IA; Wiener-Kronish JP; Sawa T
Burns; 2005 Mar; 31(2):153-8. PubMed ID: 15683685
[TBL] [Abstract][Full Text] [Related]
27. Protection against pulmonary infection with Pseudomonas aeruginosa following immunization with P. aeruginosa-pulsed dendritic cells.
Worgall S; Kikuchi T; Singh R; Martushova K; Lande L; Crystal RG
Infect Immun; 2001 Jul; 69(7):4521-7. PubMed ID: 11401995
[TBL] [Abstract][Full Text] [Related]
28. [Antigenic properties of Pseudomonas aeruginosa anatoxin and the protective action of antitoxic anti-Pseudomonas aeruginosa serum].
Podgornaia LG; Dziuban NF
Zh Mikrobiol Epidemiol Immunobiol; 1986 Jun; (6):67-9. PubMed ID: 3092510
[TBL] [Abstract][Full Text] [Related]
29. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
Pier G
Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
[TBL] [Abstract][Full Text] [Related]
30. A multicomponent Pseudomonas aeruginosa vaccine consisting of toxoids of protease, elastase, exotoxin A and a common protective antigen (OEP). Application in patients with diffuse panbronchiolitis.
Homma JY; Tanimoto H
Antibiot Chemother (1971); 1987; 39():215-21. PubMed ID: 3118783
[No Abstract] [Full Text] [Related]
31. [Morphological study of the organs and tissues of mice infected after a burn with a Pseudomonas aeruginosa strain and treated with a Pseudomonas aeruginosa polyvalent corpuscular vaccine and tobramycin].
Moroz AF; Kharitonova AM; Chanturiia TsK
Antibiotiki; 1983 May; 28(5):341-5. PubMed ID: 6410985
[TBL] [Abstract][Full Text] [Related]
32. Treatment of experimental burn wound sepsis by postburn immunization with polyvalent Pseudomonas antigen.
Nance FC; Hines JL; Fulton RE; Bornside GH
Surgery; 1970 Jul; 68(1):248-53. PubMed ID: 10483476
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model.
Bakht Azad S; Nikokar I; Faezi S; Rasooly S; Mahdavi M
Microb Pathog; 2018 Oct; 123():426-432. PubMed ID: 30075242
[TBL] [Abstract][Full Text] [Related]
34. [Antibody titers in the serum of patients vaccinated with the multicomponent vaccine consisting of toxoids of protease, elastase and a common protective antigen (OEP)].
Yamamoto M; Kubota Y; Matsuura M; Homma JY
Kansenshogaku Zasshi; 1986 Nov; 60(11):1178-83. PubMed ID: 3102639
[No Abstract] [Full Text] [Related]
35. Conjugate vaccines against Pseudomonas aeruginosa and malaria.
Cryz SJ; Sadoff JC; Que JU
Contrib Microbiol Immunol; 1989; 10():166-89. PubMed ID: 2510972
[No Abstract] [Full Text] [Related]
36. [Pseudomonas multicomponent vaccine in major burn patients].
Mizuno H; Ashikawa K
Nihon Rinsho; 1991 Oct; 49(10):2425-30. PubMed ID: 1749100
[No Abstract] [Full Text] [Related]
37. The immunoprophylaxis and immunotherapy of Pseudomonas infections in burns with polyvalent Pseudomonas aeruginosa corpuscular vaccine.
Ionescu A; Meitert E; Vasiliu S; Meitert T; Milicescu S; Sima F; Savulian C
Arch Roum Pathol Exp Microbiol; 1979; 38(3-4):317-30. PubMed ID: 122594
[No Abstract] [Full Text] [Related]
38. Efficacy of human gamma-globulin preparation in experimental pseudomonas aeruginosa infections in mice and its mode of action.
Kamimura T
Arzneimittelforschung; 1984; 34(11):1528-34. PubMed ID: 6084512
[TBL] [Abstract][Full Text] [Related]
39. [Pseudomonas aeruginosa preparations for active immunization].
Nazarchuk LV
Vrach Delo; 1991 Jul; (7):22-7. PubMed ID: 1771827
[No Abstract] [Full Text] [Related]
40. Studies on phagocytosis of mucoid and nonmucoid variants of Pseudomonas aeruginosa. I. Induction of homologous immunity by nonmucoid strains of P. aeruginosa.
Gościniak G; Grzybek-Hryncewicz K
Arch Immunol Ther Exp (Warsz); 1988; 36(2):177-84. PubMed ID: 2467637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
